Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio

The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.

Partners shaking hands . in city environment
Gilead, Arcus agreed to an expansive, long-term R&D partnership

Gilead Sciences Inc. and Arcus Biosciences Inc. unveiled a 10-year immuno-oncology R&D collaboration on 27 May that brings the larger firm significant pipeline option rights with substantial downstream earning potential for the smaller company. Analysts uniformly praised the deal from Gilead’s standpoint, both in terms of what it adds in IO and the flexibility it offers; Arcus investors, however, responded negatively to the news.

Recent speculation suggested Gilead might be looking to acquire Arcus and its pipeline and discovery engine focused on the adenosine...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

Cogent Peaks With Bezaclastinib SUMMIT Results

 

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.

France’s AB Science Plots Pivotal Masitinib Trial In Prostate Cancer

 
• By 

Still holding out hope after multiple rejections for the tyrosine kinase inhibitor.

In Brief: Concentra Snaps Up Struggling IGM Biosciences In Latest Biotech Deal

 

Concentra Biosciences is acquiring struggling IGM Biosciences for $1.25 per share plus a contingent value right, with the deal expected to close in August 2025.